Cloudbreak®
Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.
DFCs have the potential to treat and prevent other life-threatening viruses, including SARS-CoV-2. Preclinical and discovery efforts are ongoing including investigations on dual acting DFCs that combine influenza and SARS targeting groups.
Preclinical evidence shows DFCs engineered against the ACE2 receptor-binding region of the spike protein of SARS-COV-2 are potent and broad spectrum.
Subscribe here for updates.
